Paratek Announces Presentation at Piper Jaffray's Healthcare Conference

Jan 24, 2005, 00:00 ET from Paratek Pharmaceuticals, Inc.

    BOSTON, Jan. 24 /PRNewswire/ -- Paratek Pharmaceuticals, Inc. today
 announced that its Chief Executive Officer, Thomas J. Bigger, will present an
 overview of the Company's strategy and research programs at the Piper Jaffray
 17th Annual Healthcare Conference in New York City.  Details of the
 presentation follow:
      Date:          Wednesday, January 26, 2005
      Time:          1:55 p.m. (EST)
      Location:      The Pierre Hotel; Regency A room
      Speaker:       Thomas J. Bigger, Chief Executive Officer
     Mr. Bigger's presentation will review Paratek's Tetracycline ("TET") and
 Multiple Adaptational Response ("MAR") Programs, as well as the Company's
 most recent efforts to leverage its compounds and their unique mechanisms of
 action in selected anti-inflammatory and neurodegenerative conditions
 including multiple sclerosis.
     A copy of the Paratek presentation will be available upon request.
     About Paratek Pharmaceuticals
     Paratek Pharmaceuticals, Inc. is engaged in the discovery and
 commercialization of new therapeutics that treat serious and life-threatening
 diseases, with a particular focus on the growing worldwide problem of
 antibiotic resistance.  Paratek's lead programs are advancing novel compounds
 that can circumvent or block bacterial resistance, as well as drugs that can
 prevent infection by interfering with Multiple Adaptational Response ("MAR")
 mechanisms in bacteria.  Out of these efforts, Paratek has discovered a new
 class of antibiotics, the aminomethylcyclines, that target the need for new
 and potent antibacterials to overcome the problem of rapidly growing bacterial
 resistance.  The Company's lead antibiotic clinical candidate, BAY 73-7388,
 the first product from this class, is being developed in a collaborative
 partnership with Bayer HealthCare AG for the treatment of serious infections.
     Outside the antibacterial therapeutic area, Paratek has also established
 an internal effort to exploit its novel families of compounds and their unique
 mechanism of action in selected anti-inflammatory and neurodegenerative
 conditions.  Paratek has an active chemical synthesis effort to produce novel
 and diverse small molecules, with the goal of developing non-antibacterial
 products with improved activity in serious diseases based upon a growing body
 of clinical and basic research supporting this approach.
     Paratek is privately held and headquartered in Boston, Massachusetts, USA.
 For more information, visit Paratek's website at

SOURCE Paratek Pharmaceuticals, Inc.